I am a
Home I AM A Search Login

Papers of the Week

2023 Jan

Lancet HIV



Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.


Gupta SK, Berhe M, Crofoot G, Benson P, Ramgopal M, Sims J, McDonald C, Ruane P, Sanchez WE, Scribner A, Liu S-Y, VanderVeen LA, Dvory-Sobol H, Rhee MS, Baeten JM, Koenig E
Lancet HIV. 2023 Jan; 10(1):e15-e23.
PMID: 36566079.


Antiretroviral agents with novel mechanisms and dosing intervals could expand treatment options for people with HIV. Lenacapavir, an inhibitor of capsid protein that makes use of a unique mechanism, can be administered orally or subcutaneously. We sought to explore the efficacy of lenacapavir in various combination regimens as initial and maintenance therapy for HIV.